Skip to main content
Open Access Publications from the University of California

Memory t cell proliferation before hepatitis c virus therapy predicts antiviral immune responses and treatment success

  • Author(s): Méndez-Lagares, G
  • Lu, D
  • Chen, C
  • Terrault, N
  • Segal, MR
  • Khalili, M
  • Monto, A
  • Shen, H
  • Michele Manos, M
  • Lanier, LL
  • Ryan, JC
  • McCune, JM
  • Hartigan-O’Connor, DJ
  • et al.

Copyright © 2018 by The American Association of Immunologists, Inc. The contribution of the host immune system to the efficacy of new anti-hepatitis C virus (HCV) drugs is unclear. We undertook a longitudinal prospective study of 33 individuals with chronic HCV treated with combination pegylated IFN-a, ribavirin, and telaprevir/boceprevir. We characterized innate and adaptive immune cells to determine whether kinetics of the host response could predict sustained virologic response (SVR). We show that characteristics of the host immune system present before treatment were correlated with successful therapy. Augmentation of adaptive immune responses during therapy was more impressive among those achieving SVR. Most importantly, active memory T cell proliferation before therapy predicted SVR and was associated with the magnitude of the HCV-specific responses at week 12 after treatment start. After therapy initiation, the most important correlate of success was minimal monocyte activation, as predicted by previous in vitro work. In addition, subjects achieving SVR had increasing expression of the transcription factor T-bet, a driver of Th1 differentiation and cytotoxic effector cell maturation. These results show that host immune features present before treatment initiation predict SVR and eventual development of a higher frequency of functional virus-specific cells in blood. Such host characteristics May also be required for successful vaccine-mediated protection.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Main Content
Current View